Overview
Axmed, a Swiss healthtech company, has secured €5 million ($6 million) in non-dilutive grant funding from the Gates Foundation to enhance access to affordable medicines in low- and middle-income countries. This funding adds to a previous €4.2 million ($5 million) award, bringing total funding to €11 million ($13 million). The company aims to streamline procurement and delivery of essential medicines, achieving significant cost savings and expanding its reach to 50 million patients within three years.
Products
Loading...
Recent Deals
Axmed, a Swiss healthtech company, has secured €5 million ($6 million) in non-dilutive grant funding from the Gates Foundation to enhance access to affordable medicines in low- and middle-income countries. This funding adds to a previous €4.2 million ($5 million) award, bringing total funding to €11 million ($13 million). The company aims to streamline procurement and delivery of essential medicines, achieving significant cost savings and expanding its reach to 50 million patients within three years.